SUPREME COURT REVIEW OF VACCINE INJURY TRUST FUND CASE
Executive Summary
SUPREME COURT REVIEW OF VACCINE INJURY TRUST FUND CASE will likely focus on the extent to which pre-existing conditions are to be considered in determining whether a child has been injured by administration of a covered vaccine. On Oct. 31, the Supreme Court granted a writ of certiorari to accept Shalala v. Whitecotton and review a February ruling by the D.C. circuit Court ordering HHS to pay compensation to Margaret Whitecotton for a claim of encephalopathy following administration of a diphtheria-pertussis- tetanus booster in 1975.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: